Targeted Medical Pharma, Inc.
TRGM
$0.00
$0.000.00%
| 12/31/2015 | 09/30/2015 | 06/30/2015 | 03/31/2015 | 12/31/2014 | |
|---|---|---|---|---|---|
| Revenue | -9.00% | -6.67% | -39.58% | -40.70% | -46.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.00% | -6.67% | -39.58% | -40.70% | -46.21% |
| Cost of Revenue | -21.25% | 0.32% | 4.82% | -1.55% | -9.82% |
| Gross Profit | 1.41% | -9.62% | -52.82% | -58.35% | -59.96% |
| SG&A Expenses | -38.81% | -40.31% | -33.90% | -13.11% | 1.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.63% | -33.13% | -26.07% | -12.28% | -3.07% |
| Operating Income | 67.12% | 97.53% | -286.56% | -59.75% | -5,681.50% |
| Income Before Tax | 59.22% | 76.54% | -52.83% | -72.23% | -398.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 59.22% | 76.54% | -29.06% | -72.23% | -398.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.80% | 76.54% | -29.06% | -72.23% | -398.31% |
| EBIT | 67.12% | 97.53% | -286.56% | -59.75% | -5,681.50% |
| EBITDA | 69.23% | 105.93% | -8,808.33% | -76.25% | -930.07% |
| EPS Basic | 62.23% | 77.23% | -26.88% | -66.76% | -379.40% |
| Normalized Basic EPS | 63.22% | 77.41% | -49.41% | -52.77% | -363.64% |
| EPS Diluted | 62.23% | 77.23% | -26.88% | -66.76% | -379.40% |
| Normalized Diluted EPS | 63.22% | 77.41% | -49.41% | -52.77% | -363.64% |
| Average Basic Shares Outstanding | 3.83% | 3.45% | 1.99% | 3.34% | 6.89% |
| Average Diluted Shares Outstanding | 3.83% | 3.45% | 1.99% | 3.34% | 6.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
